Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
Scienture (NASDAQ:SCNX) has achieved a major commercialization milestone with the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its distribution center and receipt of its first wholesaler order for August 2025.
Arbli™, the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market, is indicated for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients.
The product addresses a significant market opportunity, with U.S. losartan sales reaching $276 million annually and a global market of approximately $1.5 billion in 2024. Arbli™ is protected by two USPTO patents and offers advantages over traditional tablet formulations.
Scienture Holdings (NASDAQ: SCNX) has secured $1.2 million in bridge funding through common stock issuance to institutional/accredited investors, as part of a larger approved raise of up to $3 million. The funding excludes any additional dilutive securities like warrants or options.
The capital will support upcoming commercial product launches and pipeline program development. The company's leadership, including Executive Chairman Shankar Hariharan and Co-CEO Narasimhan Mani, emphasized that this funding reflects investor confidence in their strategy to develop and market specialty pharmaceutical products.
Scienture Holdings (NASDAQ:SCNX) has successfully regained compliance with Nasdaq's minimum bid price requirement by maintaining a closing bid price of $1.00 or higher for ten consecutive business days. This resolves the non-compliance notice received on May 19, 2025, which had given the company until November 17, 2025, to meet the listing requirement.
The company's leadership expressed satisfaction with this development, particularly as they prepare for the upcoming launch of their first FDA-approved product, Arbli™. The management team emphasized their continued focus on creating stockholder value and bringing novel therapies to market.
Scienture Holdings (NASDAQ: SCNX) announces FDA Orange Book listing of two patents for Arbli™, their losartan potassium oral suspension. The patents (11890273 and 12156869), expiring in October 2041, cover stable liquid formulations and treatment methods for Arbli™, the first FDA-approved ready-to-use oral liquid losartan in the U.S.
Arbli™ (10mg/mL) is approved for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients. The product addresses the limitations of current tablet-only options, eliminating compounding risks and offering convenient dosing.
According to IQVIA data (March 2025), the U.S. losartan market shows annual sales of $276 million with 69 million prescriptions.
Scienture Holdings (NASDAQ: SCNX) has announced manufacturing and supply chain readiness for Arbli™, their FDA-approved oral liquid losartan suspension (10mg/mL), targeting a commercial launch in July 2025. The company's subsidiary has partnered with Saptalis Pharmaceuticals for manufacturing and secured agreements for warehousing and distribution.
Arbli™ is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market, designed for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients. The product holds two USPTO patents pending FDA Orangebook listing.
According to IQVIA data (MAT December 2024), the U.S. losartan market has annual sales of $292 million with 68 million prescriptions. Unlike current market offerings that require compounding from tablets, Arbli™ offers a ready-to-use liquid formulation with reduced dosing volume and room temperature storage stability.
Scienture Holdings (NASDAQ: SCNX) has announced the divestiture of its Healthcare IT and Wholesale Operations subsidiaries - Integra Pharma Solutions, Bonum Health, and Softell - to Tollo Health for $5 million. This strategic move is part of the company's broader realignment to focus exclusively on its Branded and Specialty Pharma segment through Scienture,
The proceeds from the sale will support commercial and strategic product development activities at Scienture, The divestiture aims to achieve three key benefits:
- Increased operational efficiency through streamlined structure
- Cost savings through consolidation of overlapping functions
- Dedicated focus on commercial products and high-value product pipeline
Scienture Holdings (NASDAQ: SCNX) has transformed from a health services IT company to a specialty pharmaceutical company through strategic moves in 2024-2025. The company completed a $22.5M sale of TRXaDE Inc. assets and merged with Scienture Inc. in a $103M all-stock transaction.
The company now has two FDA-approved commercial products scheduled for launch in H2 2025: ArbliTM (in-house developed) and REZENOPY® (acquired in March 2025). The company's pipeline includes multiple products under development:
- SCN-104: Injectable pen for migraine treatment
- SCN-106: CVS therapeutic biosimilar
- SCN-107: Non-opioid post-surgical pain management
REZENOPY®, a 10mg naloxone HCl nasal spray, targets a market with annual sales of $189M. The combined market opportunity for their two commercial products is $481M, based on IQVIA data (December 2024).
SCIENTURE HOLDINGS (NASDAQ: SCNX) has announced two significant developments in its commercial operations. First, Michele Rath has been appointed as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, , effective November 1, 2024. Rath brings over 20 years of industry experience from previous roles at Pfizer, CVS Caremark, and Aurobindo Pharma.
Second, the company has established a strategic partnership with Syneos Health Commercial Services through a Master Commercial Services Agreement (MCSA). Syneos Health will serve as Scienture's Contract Sales Organization, providing field sales, inside sales, and customer engagement services supported by their Kinetic platform analytics.
These developments aim to support the upcoming launches of two FDA-approved products: Arbli™ (losartan potassium) oral suspension and Rezenopy® (naloxone HCl) nasal spray.